文献速递淋巴瘤

Idelalisib联合利妥昔单抗对比伊布替尼治疗复发/难治性慢性淋巴细胞白血病:来自CLLEAR患者登记的真实世界分析

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
PubMed 文献 · Br J Haematol · 2023-03-27

该真实世界回顾性分析比较了Idelalisib联合利妥昔单抗(R-idela,n=171)与伊布替尼(n=244)治疗复发/难治性慢性淋巴细胞白血病(CLL)的疗效与耐受性。伊布替尼组中位无进展生存期(40.5个月 vs 22.0个月,p<0.001)和中位总生存期(54.4个月 vs 37.7个月,p=0.04)均显著更长;多因素分析中仅无进展生存期差异仍显著。伊布替尼在常规实践中疗效与耐受性均优于R-idela。

要点

  • 伊布替尼组中位无进展生存期40.5个月,显著长于R-idela组的22.0个月(p<0.001)。
  • 伊布替尼组中位总生存期54.4个月,显著长于R-idela组的37.7个月(p=0.04)。
  • R-idela组因毒性停药比例39.8%,高于伊布替尼组的22.5%。

核心结论

  • 在常规实践中,伊布替尼治疗复发/难治性CLL的疗效与耐受性均显著优于Idelalisib联合利妥昔单抗。
  • R-idela方案对无合适替代治疗的高度选择患者仍可考虑为合理选择。

研究设计与样本

  • 真实世界回顾性分析,纳入复发/难治性CLL患者,R-idela组171例,伊布替尼组244例。
  • 中位年龄R-idela组70岁,伊布替尼组69岁;两组中位既往治疗线数均为2线。

主要发现

  • R-idela组对比伊布替尼组,TP53异常有更高趋势(53% vs 44%,p=0.093),复杂核型也有更高趋势(57% vs 46%,p=0.083)。
  • 伊布替尼组中位无进展生存期40.5个月,显著长于R-idela组的22.0个月(p<0.001)。
  • 伊布替尼组中位总生存期54.4个月,显著长于R-idela组的37.7个月(p=0.04)。
  • 多因素分析中,仅无进展生存期在两组间仍保持显著差异,总生存期未保持显著差异。
  • 治疗中断最常见原因为毒性(R-idela组39.8% vs 伊布替尼组22.5%)和CLL进展(R-idela组27.5% vs 伊布替尼组11.1%)。

关键数值与推荐

  • R-idela组TP53异常53% vs 伊布替尼组44%(p=0.093)。
  • R-idela组复杂核型57% vs 伊布替尼组46%(p=0.083)。
  • 伊布替尼组中位无进展生存期40.5个月 vs R-idela组22.0个月(p<0.001)。
  • 伊布替尼组中位总生存期54.4个月 vs R-idela组37.7个月(p=0.04)。

临床怎么用

  • 作者认为,R-idela方案对无合适替代治疗的高度选择患者仍可考虑为合理选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idelalisib (idela), a phosphatidylinositol 3-kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R-idela) versus ibrutinib have been conducted. Therefore, we performed a real-world retrospective analysis of patients with R/R CLL treated with R-idela (n = 171) or ibrutinib (n = 244). The median age was 70 versus 69 years, with a median of two previous lines. There was a trend towards higher tumour protein p53 (TP53) aberrations and complex karyotype in the R-idela group (53% vs. 44%, p = 0.093; 57% vs. 46%, p = 0.083). The median progression-free survival (PFS) was significantly longer with ibrutinib (40.5 vs. 22.0 months; p < 0.001); similarly to overall survival (OS; median 54.4 vs. 37.7 months, p = 0.04). In multivariate analysis, only PFS but not OS remained significantly different between the two agents. The most common reasons for treatment discontinuation included toxicity (R-idela, 39.8%; ibrutinib, 22.5%) and CLL progression (27.5% vs. 11.1%). In conclusion, our data show significantly better efficacy and tolerability of ibrutinib over R-idela in patients with R/R CLL treated in routine practice. The R-idela regimen may still be considered a reasonable option in highly selected patients without a suitable treatment alternative.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Špaček M, Smolej L, Šimkovič M, et al. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). Br J Haematol. 2023. PMID: 36971061. doi:10.1111/bjh.18736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。